Galena Biopharma Inc
Change company Symbol lookup
Select an option...
GALE Galena Biopharma Inc
BRK.B Berkshire Hathaway Inc
ORXCF Orix Corp
NAVI Navient Corp
CAKE Cheesecake Factory Inc
XFRBX Blackrock Floating Rate Income Strategies Fund II Inc
JPM JPMorgan Chase & Co
MTX Minerals Technologies Inc
XBIT XBiotech Inc
XCIIX BlackRock Enhanced Capital And Income Fund Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap BlendCompany profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Price
Delayed
$0.58
Day's Change
-0.0126 (-2.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.60
Day's Low
0.5766
Volume
(Average)

Today's volume of 313,205 shares is on pace to be in-line with GALE's 10-day average volume of 498,972 shares.

313,205
  • Prev Close
    0.5926
  • Today's Open
    0.59
  • Day's Range
    0.5766-0.60
  • Avg Vol (10-day)
    499.0K
  • Last (time)
    2:01p ET 05/25/17
  • Last (size)
    100
  • 52-Wk Range
    0.5215 - 49.80
    LowHigh
  • (06/20/16 - 05/03/17)
    11.22%
  • 206.6%
  • Market Cap
    21.7M
  • Shares Outstanding
    37.4M
  • 0.22
  • 2.57x
  • No dividend
  • Ex-dividend
    No dividend
  • 1.9
  • 28.52
  • (% of float 05/15/17)
    18.05

Latest News

May 10, 2017
4:30 pm ET
Globe Newswire
April 13, 2017
10:10 am ET
Globe Newswire
April 12, 2017
1:34 pm ET
PR Newswire
April 07, 2017
7:00 am ET
PR Newswire
April 05, 2017
1:52 pm ET
BusinessWire
April 04, 2017
10:45 pm ET
BusinessWire
1:43 pm ET
BusinessWire
7:05 am ET
Globe Newswire
April 03, 2017
3:47 pm ET
PR Newswire
March 31, 2017
5:20 pm ET
PR Newswire
March 27, 2017
2:27 pm ET
BusinessWire
March 24, 2017
7:01 pm ET
PR Newswire
March 17, 2017
5:12 pm ET
Globe Newswire
7:05 am ET
Globe Newswire
March 15, 2017
7:17 pm ET
Globe Newswire
4:15 pm ET
Globe Newswire
March 10, 2017
10:10 am ET
Globe Newswire
March 09, 2017
7:05 am ET
Globe Newswire
March 07, 2017
9:00 am ET
Globe Newswire
March 03, 2017
3:58 pm ET
Globe Newswire
February 08, 2017
9:01 am ET
MarketWatch
8:34 am ET
MarketWatch
February 06, 2017
9:09 am ET
MarketWatch
9:09 am ET
MarketWatch
7:30 am ET
MarketWatch
7:14 am ET
MarketWatch
December 28, 2016
9:04 am ET
MarketWatch
8:58 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , , and

Copyright © 2017. All rights reserved.